oncology
Medicines

VTE risk with checkpoint inhibitors

Cancer patients treated with immune checkpoint inhibitors have been shown to have an increased risk of venous thromboembolism (VTE) and a poorer prognosis. A retrospective Austrian study of 673 patients treated with a checkpoint inhibitor between 2015 and 2018 found 12.9% developed a VTE over a median follow-up period of 8.5 months.. Patients had a ...

Already a member?

Login to keep reading.


OR
© 2020 the limbic